[96a5a0]: / output / allTrials / identified / NCT00050960_identified.json

Download this file

267 lines (267 with data), 11.3 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
{
"info": {
"nct_id": "NCT00050960",
"official_title": "Randomized Phase III Trial Comparing Targretin Capsules/Carboplatin/Paclitaxel Versus Carboplatin/Paclitaxel in Chemotherapy-Naïve Patients With Advanced or Metastatic Non-Small Cell Lung Cancer",
"inclusion_criteria": "Healthy volunteers allowed",
"exclusion_criteria": "",
"miscellaneous_criteria": "Patients must have:\n\n* Pathologic (histologic or cytologic) confirmation of NSCLC\n* Stage IIIB with malignant pleural effusion or Stage IV disease\n* At least one measurable or evaluable NSCLC lesion that has not been previously irradiated unless radiation therapy was more than three weeks prior to entry in the study and the lesion has been shown to have progressed subsequent to the radiation therapy\n* ECOG performance status 0 or 1\n* Adequate organ system function\n* Fasting serum triglycerides that are within the age-adjusted normal range (or normalized with appropriate intervention such as antilipid therapy prior to the initiation of Targretin capsule therapy).\n\nPatients must be able to complete at least four cycles of combination chemotherapy (i.e., approximately four months)\n\nPatients must not have had:\n\n* Brain metastasis\n* Prior chemotherapy for NSCLC\n* Prior platinum-based chemotherapy for any indication"
},
"inclusion_lines": [
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
}
],
"exclusion_lines": [],
"miscellaneous_lines": [
{
"line": "* Pathologic (histologic or cytologic) confirmation of NSCLC",
"criterions": [
{
"exact_snippets": "Pathologic (histologic or cytologic) confirmation of NSCLC",
"criterion": "NSCLC",
"requirements": [
{
"requirement_type": "confirmation",
"expected_value": "pathologic (histologic or cytologic)"
}
]
}
]
},
{
"line": "* Stage IIIB with malignant pleural effusion or Stage IV disease",
"criterions": [
{
"exact_snippets": "Stage IIIB with malignant pleural effusion",
"criterion": "cancer stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "IIIB"
},
{
"requirement_type": "condition",
"expected_value": "malignant pleural effusion"
}
]
},
{
"exact_snippets": "Stage IV disease",
"criterion": "cancer stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "IV"
}
]
}
]
},
{
"line": "* At least one measurable or evaluable NSCLC lesion that has not been previously irradiated unless radiation therapy was more than three weeks prior to entry in the study and the lesion has been shown to have progressed subsequent to the radiation therapy",
"criterions": [
{
"exact_snippets": "At least one measurable or evaluable NSCLC lesion",
"criterion": "NSCLC lesion",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "N/A"
}
},
{
"requirement_type": "measurability",
"expected_value": [
"measurable",
"evaluable"
]
}
]
},
{
"exact_snippets": "NSCLC lesion ... that has not been previously irradiated",
"criterion": "NSCLC lesion irradiation status",
"requirements": [
{
"requirement_type": "irradiation status",
"expected_value": false
}
]
},
{
"exact_snippets": "NSCLC lesion ... unless radiation therapy was more than three weeks prior to entry in the study",
"criterion": "NSCLC lesion irradiation timing",
"requirements": [
{
"requirement_type": "irradiation timing",
"expected_value": {
"operator": ">",
"value": 3,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "NSCLC lesion ... the lesion has been shown to have progressed subsequent to the radiation therapy",
"criterion": "NSCLC lesion progression post-radiation",
"requirements": [
{
"requirement_type": "progression",
"expected_value": true
}
]
}
]
},
{
"line": "* ECOG performance status 0 or 1",
"criterions": [
{
"exact_snippets": "ECOG performance status 0 or 1",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "value",
"expected_value": [
"0",
"1"
]
}
]
}
]
},
{
"line": "* Adequate organ system function",
"criterions": [
{
"exact_snippets": "Adequate organ system function",
"criterion": "organ system function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
}
]
},
{
"line": "* Fasting serum triglycerides that are within the age-adjusted normal range (or normalized with appropriate intervention such as antilipid therapy prior to the initiation of Targretin capsule therapy).",
"criterions": [
{
"exact_snippets": "Fasting serum triglycerides that are within the age-adjusted normal range",
"criterion": "fasting serum triglycerides",
"requirements": [
{
"requirement_type": "range",
"expected_value": "age-adjusted normal range"
}
]
},
{
"exact_snippets": "normalized with appropriate intervention such as antilipid therapy",
"criterion": "fasting serum triglycerides",
"requirements": [
{
"requirement_type": "normalization",
"expected_value": true
}
]
}
]
},
{
"line": "Patients must be able to complete at least four cycles of combination chemotherapy (i.e., approximately four months)",
"criterions": [
{
"exact_snippets": "Patients must be able to complete at least four cycles of combination chemotherapy",
"criterion": "ability to complete chemotherapy cycles",
"requirements": [
{
"requirement_type": "minimum number of cycles",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "cycles"
}
}
]
}
]
},
{
"line": "* Brain metastasis",
"criterions": [
{
"exact_snippets": "Brain metastasis",
"criterion": "brain metastasis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Prior chemotherapy for NSCLC",
"criterions": [
{
"exact_snippets": "Prior chemotherapy for NSCLC",
"criterion": "chemotherapy for NSCLC",
"requirements": [
{
"requirement_type": "prior treatment",
"expected_value": true
}
]
}
]
},
{
"line": "* Prior platinum-based chemotherapy for any indication",
"criterions": [
{
"exact_snippets": "Prior platinum-based chemotherapy",
"criterion": "platinum-based chemotherapy",
"requirements": [
{
"requirement_type": "prior treatment",
"expected_value": true
}
]
}
]
}
],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": [
{
"line": "Patients must have:",
"criterions": []
},
{
"line": "Patients must not have had:",
"criterions": []
}
]
}